Can you take Metformin and Berberine together?

The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

Rankings / Comparisons

Metformin vs Berberine

The "nature's metformin" question — does the botanical actually substitute for the drug?

Reviewed by Read Off Label · How we grade

Score comparison

Metformin has the higher descriptive composite (B+, 7.2/10) compared with Berberine (B-, 6.3/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.

Metformin

B+ 7.2/10

aka Glucophage, Glumetza, Fortamet, Riomet

Evidence: Strong (in T2D); Moderate observationally (non-diabetics); Preclinical (pure anti-aging) (8/10)
Benefit: Varies (5/10)
Risk: Low-Med (GI side effects; B12 deficiency with chronic use; lactic acidosis rare; may blunt exercise adaptations) (7/10 safety)
Legality: Rx (off-label for longevity)
Dose / route context: 500-2000 mg/day PO; clinical titration commonly begins at 500 mg with meals
Class: Prescription
Last reviewed: Jul 1, 2026

Read Off Label grades Metformin as B+ (7.2/10) based on strong evidence, variable benefit magnitude, and a low-med-risk safety profile.

UKPDS showed 36% reduction in all-cause mortality in T2D.

Studied, labeled, or reported-use context: 500-2000 mg/day PO; clinical titration commonly begins at 500 mg with meals — Rx; not individualized guidance.

What it is

UKPDS showed 36% reduction in all-cause mortality in T2D. TAME trial ($75M, 3000 non-diabetic older adults) repeatedly delayed — FDA approved design but unfunded. 2019 Konopka data: may blunt exercise-induced mitochondrial adaptations.

Mechanism

Complex I mild inhibition → AMPK activation → mTOR inhibition; improved insulin sensitivity; possible gut microbiome effects; reduced hepatic gluconeogenesis

Full Metformin review →

Berberine

B- 6.3/10

aka Dihydroberberine, BBR

Evidence: Moderate (glycemic control — comparable to metformin in small trials; lipid modification — ~0.5 mmol/L LDL reduction) (6/10)
Benefit: Moderate (5/10)
Risk: Low-Med (GI upset common — diarrhea, cramping; significant CYP3A4 inhibition → drug interactions; not safe in pregnancy) (7/10 safety)
Legality: OTC
Dose / route context: 500 mg 2-3x/day with meals; dihydroberberine (Glucovantage) claims better bioavailability
Class: Supplement
Last reviewed: Jul 11, 2026

Read Off Label grades Berberine as B- (6.3/10) based on moderate evidence, moderate benefit magnitude, and a low-med-risk safety profile.

The 'nature's Ozempic' TikTok rebrand inflated hype beyond evidence.

Studied, labeled, or reported-use context: 500 mg 2-3x/day with meals; dihydroberberine (Glucovantage) claims better bioavailability — OTC; not individualized guidance.

What it is

The 'nature's Ozempic' TikTok rebrand inflated hype beyond evidence. Legitimate mechanism and moderate effects on glucose and lipids. CYP3A4 interactions are underappreciated — affects many common drugs including statins, calcium channel blockers, warfarin. Poor bioavailability native — dihydroberberine has better PK.

Mechanism

Alkaloid from Berberis/goldenseal/Coptis; AMPK activator (metformin-like); inhibits PCSK9 expression; modulates gut microbiome; glucose-lowering via multiple mechanisms

Full Berberine review →

Common questions

How do the evidence profiles of Metformin and Berberine compare?: Metformin has the higher descriptive composite (B+, 7.2/10) compared with Berberine (B-, 6.3/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.
What's the difference between Metformin and Berberine?: The "nature's metformin" question — does the botanical actually substitute for the drug?
Can you take Metformin and Berberine together?: The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

This is an independent synthesis of published research by a non-clinician. The comparison reports composite and axis-level differences without selecting an intervention for the reader. Relevance depends on indication, population, dose, duration, and other context. See the full disclaimer and methodology.